# Phase 3 Carcinoma, Hepatocellular trials: 34 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 34 trials in phase 3 for Carcinoma, Hepatocellular that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Carcinoma, Hepatocellular trials: 34 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/carcinoma-hepatocellular

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 34
- Recruiting or not yet: 34
- Read on: November 19, 2026

## Trials

The 25 newest of 34, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 26, 2026 | NCT07895732 | Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma | University Health Network, Toronto | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895732) |
| September 23, 2026 | NCT07836530 | Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma | BeOne Medicines | Phase 3 | Recruiting | Hepatocellular Carcinoma, Liver Cancer | 492 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836530) |
| September 16, 2026 | NCT07823348 | JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer | Shanghai Junshi Bioscience Co., Ltd. | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823348) |
| September 10, 2026 | NCT07813572 | ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 | Recruiting | Hepatocellular Carcinoma | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813572) |
| July 9, 2026 | NCT07691762 | A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma | 690 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691762) |
| May 18, 2026 | NCT07594340 | HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven) | Sponsor not shown (see the record) | Phase 3 | Recruiting | Hepatocellular Carcinoma | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594340) |
| April 17, 2026 | NCT07537946 | Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer | Tongji Hospital | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma (HCC), Metastases | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07537946) |
| March 16, 2026 | NCT07475026 | A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence | Tianjin Medical University Cancer Institute and Hospital | Phase 3 | Recruiting | HCC - Hepatocellular Carcinoma | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07475026) |
| March 10, 2026 | NCT07461675 | Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection | University of Geneva, Switzerland | Phase 3 | Not yet recruiting | Hepato Cellular Carcinoma (HCC), Immunotherapy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07461675) |
| February 18, 2026 | NCT07417397 | Adjuvant TACE in HCC With High-risk Recurrence Factors | Guangxi Medical University | Phase 3 | Recruiting | Hepatocellular Carcinoma, Adjuvant, Transarterial Chemoembolization | 442 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07417397) |
| February 2, 2026 | NCT07381660 | SBRT Versus Surgical Resection for Small HCC | Sun Yat-sen University | Phase 3 | Recruiting | Hepatocellular Carcinoma (HCC) | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07381660) |
| January 21, 2026 | NCT07356037 | Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Cachexia, Hepatocellular Carcinoma | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07356037) |
| January 7, 2026 | NCT07322848 | DEB-TACE vs cTACE in HCC After TIPS | First Affiliated Hospital, Sun Yat-Sen University | Phase 3 | Recruiting | Hepatocellular Carcinoma (HCC), TACE, TIPS, DEB-TACE, cTACE | 206 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07322848) |
| September 22, 2025 | NCT07186621 | Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | Recruiting | Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE, Narrow Margin | 286 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07186621) |
| September 10, 2025 | NCT07166406 | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | NRG Oncology | Phase 3 | Recruiting | Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8 | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07166406) |
| June 18, 2025 | NCT07027436 | Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for... | Hamilton Health Sciences Corporation | Phase 3 | Recruiting | Hepatocellular Carcinoma (HCC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07027436) |
| April 10, 2025 | NCT06921785 | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular... | AstraZeneca | Phase 3 | Recruiting | Hepatocellular Carcinoma | 1,220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06921785) |
| February 24, 2025 | NCT06841185 | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for... | Shanghai Henlius Biotech | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 656 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06841185) |
| February 24, 2025 | NCT06841172 | Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC | Shandong Cancer Hospital and Institute | Phase 3 | Recruiting | OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, Systemic Therapy | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06841172) |
| November 8, 2024 | NCT06680258 | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With... | Tempest Therapeutics | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 740 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06680258) |
| July 9, 2024 | NCT06492395 | Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT | Second Affiliated Hospital of Guangzhou Medical University | Phase 3 | Recruiting | Hepatocellular Carcinoma Non-resectable | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06492395) |
| April 17, 2024 | NCT06371157 | A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With... | Akeso | Phase 3 | Recruiting | Hepatocellular Carcinoma | 469 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06371157) |
| January 11, 2024 | NCT06201065 | FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled... | Sun Yat-sen University | Phase 3 | Recruiting | Hepatocellular Carcinoma | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06201065) |
| October 18, 2023 | NCT06089369 | Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion | Tongji Hospital | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06089369) |
| September 18, 2023 | NCT06041477 | Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC | Sun Yat-sen University | Phase 3 | Recruiting | Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06041477) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sun Yat-sen University | 4 |
| Second Affiliated Hospital of Guangzhou Medical University | 2 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 2 |
| Tongji Hospital | 2 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| [Suzhou Suncadia Biopharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/suzhou-suncadia-biopharmaceuticals-co-ltd) | 1 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 1 |
| Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 1 |
| [Shanghai Henlius Biotech](https://specstream.ai/data/clinical-trials/company/shanghai-henlius-biotech) | 1 |
| Guangxi Medical University | 1 |
| Hamilton Health Sciences Corporation | 1 |
| Tempest Therapeutics | 1 |
| First Affiliated Hospital, Sun Yat-Sen University | 1 |
| Shanghai Junshi Bioscience Co., Ltd. | 1 |
| University Health Network, Toronto | 1 |
| [Suzhou Zelgen Biopharmaceuticals Co.,Ltd](https://specstream.ai/data/clinical-trials/company/suzhou-zelgen-biopharmaceuticals-co-ltd) | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| [Polaris Group](https://specstream.ai/data/clinical-trials/company/polaris-group) | 1 |
| [Can-Fite BioPharma](https://specstream.ai/data/clinical-trials/company/can-fite-biopharma) | 1 |
| [Changchun GeneScience Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/changchun-genescience-pharmaceutical-co-ltd) | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 1 |
| University of Geneva, Switzerland | 1 |
| NRG Oncology | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 23 |
| Canada | 5 |
| United States | 3 |
| Australia | 2 |
| France | 2 |
| Germany | 2 |
| Italy | 2 |
| Japan | 2 |
| Spain | 2 |
| Poland | 2 |
| Taiwan | 2 |
| Vietnam | 2 |
| New Zealand | 1 |
| Austria | 1 |
| Brazil | 1 |
| Hong Kong | 1 |
| India | 1 |
| Netherlands | 1 |
| South Korea | 1 |
| Thailand | 1 |
| Turkey (Türkiye) | 1 |
| United Kingdom | 1 |
| Bosnia and Herzegovina | 1 |
| Bulgaria | 1 |
| Israel | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Educational supply stores in the United States](https://specstream.ai/data/businesses/educational-supply-stores/united-states)
- [Preschools in the United States](https://specstream.ai/data/businesses/preschools/united-states)
- [Building supply stores in the United States](https://specstream.ai/data/businesses/building-supply-stores/united-states)
- [Manufacturers in the United States](https://specstream.ai/data/businesses/manufacturers/united-states)
- [Accounting firms in the United States](https://specstream.ai/data/businesses/accounting-firms/united-states)
- [German restaurants in the United States](https://specstream.ai/data/businesses/german-restaurants/united-states)
